Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP ...

MedExpress Canada, a clinician-led online treatment and consultation service, has announced the launch of generic semaglutide. The news comes as Health Canada has approved generic semaglutide ...

The biotechnology and drug manufacturing market continues to give investors a hit-and-miss. Bears are betting heavily against Hims and Hers (HIMS), holding a short interest of 28.31%. On May 21, Hims ...

SPRINGFIELD, IL / ACCESS Newswire / May 19, 2026 / Anew analysisreleased today by 3 Axis Advisors, drawing on data from ...

Canopy, the leader in Enterprise AI for oncology, today announced two abstracts selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies ...

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking ...

Though the Tecentriq SC has created buzz, oncologists say it is not about speed. It reflects how cancer care is evolving from ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.